OBJECTIVES: To compare mortality and death or major morbidity (DOMM) among infants <25 weeks estimated gestational age (EGA) born during two post-surfactant era time periods. STUDY DESIGN AND PATIENTS: Comparative cohort study of very low birthweight (501-1500 g) infants <25 weeks EGA in the NICHD Neonatal Research Network born during two post-surfactant era time periods (group I, 1991-1994, n=1408; group II, 1995-1998, n=1348). Perinatal and neonatal factors were compared, and group related mortality and DOMM risk were evaluated. RESULTS: Mortality was higher for group I (63.1% v 56.7%; p=0.0006). Antenatal steroids (ANS) and antenatal antibiotics (AABX), surfactant (p<0.0001), and bronchopulmonary dysplasia (p=0.0008) were more prevalent in group II. In a regression model that controlled for basic and delivery factors only, mortality risk was greater for group I than for group II (odds ratio (OR) 1.4, 95% confidence interval (CI) 1.2 to 1.7); the addition of AABX and surfactant, or ANS (OR 0.97, 95% CI 0.79 to 1.2) to the model appeared to account for this difference. There was no difference in DOMM (86.8% v 88.4%; p=0.2), but risk was lower for group I in regression models that included ANS (OR 0.70, 95% CI 0.52 to 0.94). CONCLUSION: Survival to discharge was more likely during the more recent period because of group differences in ANS, AABX, and surfactant. However, this treatment shift may reflect an overall more aggressive management approach. More consistent application of treatment has led to improving survival of <25 week EGA infants during the post-surfactant era, but possibly at the cost of greater risk of major in-hospital morbidities.
OBJECTIVES: To compare mortality and death or major morbidity (DOMM) among infants <25 weeks estimated gestational age (EGA) born during two post-surfactant era time periods. STUDY DESIGN AND PATIENTS: Comparative cohort study of very low birthweight (501-1500 g) infants <25 weeks EGA in the NICHD Neonatal Research Network born during two post-surfactant era time periods (group I, 1991-1994, n=1408; group II, 1995-1998, n=1348). Perinatal and neonatal factors were compared, and group related mortality and DOMM risk were evaluated. RESULTS: Mortality was higher for group I (63.1% v 56.7%; p=0.0006). Antenatal steroids (ANS) and antenatal antibiotics (AABX), surfactant (p<0.0001), and bronchopulmonary dysplasia (p=0.0008) were more prevalent in group II. In a regression model that controlled for basic and delivery factors only, mortality risk was greater for group I than for group II (odds ratio (OR) 1.4, 95% confidence interval (CI) 1.2 to 1.7); the addition of AABX and surfactant, or ANS (OR 0.97, 95% CI 0.79 to 1.2) to the model appeared to account for this difference. There was no difference in DOMM (86.8% v 88.4%; p=0.2), but risk was lower for group I in regression models that included ANS (OR 0.70, 95% CI 0.52 to 0.94). CONCLUSION: Survival to discharge was more likely during the more recent period because of group differences in ANS, AABX, and surfactant. However, this treatment shift may reflect an overall more aggressive management approach. More consistent application of treatment has led to improving survival of <25 week EGA infants during the post-surfactant era, but possibly at the cost of greater risk of major in-hospital morbidities.
Authors: B R Vohr; L L Wright; A M Dusick; L Mele; J Verter; J J Steichen; N P Simon; D C Wilson; S Broyles; C R Bauer; V Delaney-Black; K A Yolton; B E Fleisher; L A Papile; M D Kaplan Journal: Pediatrics Date: 2000-06 Impact factor: 7.124
Authors: T M O'Shea; J M Kothadia; K L Klinepeter; D J Goldstein; B G Jackson; R G Weaver; R G Dillard Journal: Pediatrics Date: 1999-07 Impact factor: 7.124
Authors: S F Bottoms; R H Paul; B M Mercer; C A MacPherson; S N Caritis; A H Moawad; J P Van Dorsten; J C Hauth; G R Thurnau; M Miodovnik; P M Meis; J M Roberts; D McNellis; J D Iams Journal: Am J Obstet Gynecol Date: 1999-03 Impact factor: 8.661
Authors: D K Stevenson; L L Wright; J A Lemons; W Oh; S B Korones; L A Papile; C R Bauer; B J Stoll; J E Tyson; S Shankaran; A A Fanaroff; E F Donovan; R A Ehrenkranz; J Verter Journal: Am J Obstet Gynecol Date: 1998-12 Impact factor: 8.661
Authors: Hiroshi Hirakawa; Richard A Pierce; Gulbin Bingol-Karakoc; Cagatay Karaaslan; Meiqian Weng; Guo-Ping Shi; Ali Saad; Ekkehard Weber; Thomas J Mariani; Barry Starcher; Steve D Shapiro; Sule Cataltepe Journal: Am J Respir Crit Care Med Date: 2007-08-02 Impact factor: 21.405
Authors: John C Wellons; Chevis N Shannon; Abhaya V Kulkarni; Tamara D Simon; Jay Riva-Cambrin; William E Whitehead; W Jerry Oakes; James M Drake; Thomas G Luerssen; Marion L Walker; John R W Kestle Journal: J Neurosurg Pediatr Date: 2009-07 Impact factor: 2.375
Authors: Ira Adams-Chapman; Roy J Heyne; Sara B DeMauro; Andrea F Duncan; Susan R Hintz; Athina Pappas; Betty R Vohr; Scott A McDonald; Abhik Das; Jamie E Newman; Rosemary D Higgins Journal: Pediatrics Date: 2018-04-17 Impact factor: 7.124
Authors: Carl Bose; Linda J Van Marter; Matthew Laughon; T Michael O'Shea; Elizabeth N Allred; Padmani Karna; Richard A Ehrenkranz; Kim Boggess; Alan Leviton Journal: Pediatrics Date: 2009-08-17 Impact factor: 7.124